^
Association details:
| Biomarker: | KDR overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
Published date:
03/16/2021
Excerpt:
VEGFR2 expression was associated with a TTP after bevacizumab of 3 months (95% CI, 1.8-4.2) compared with a TTP of 7 months (95% CI, 5.7-8.3) in patients with no tumoral expression of VEGFR2 (p = 0.009).
DOI:
10.1038/s41598-021-85385-1
